3-Pyrrolidin-2-ylpyrazolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-Pyrrolidin-2-ylpyrazolidine
• 英文别名: 3-pyrrolidin-2-ylpyrazolidine
• 化学式: C₇H₁₅N₃
• 分子量: 141.21
• InChiKey: WJPBFABJSLKRQH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.1
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• Novel RAD51 Inhibitors and Uses Thereof
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20180057483A1

  公开（公告）日：2018-03-01

  The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

  本发明涵盖了新型RAD51抑制剂。本发明的化合物可能在预防或治疗需要的受试者中的癌症方面有用。本发明还涵盖了通过向受试者投予本发明化合物的治疗有效量来预防或治疗受试者中的癌症的方法。
• ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Aragon Pharmaceuticals, Inc.

  公开号：EP3124481A1

  公开（公告）日：2017-02-01

  Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors.

  本文描述的化合物是雄激素受体调节剂。还描述了包括本文所述化合物的药物组合物和药物，以及使用此类雄激素受体调节剂（单独使用或与其他化合物结合使用）治疗介导或依赖于雄激素受体的疾病或病症的方法。
• BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE
  申请人：Lumena Pharmaceuticals LLC

  公开号：EP3278796A1

  公开（公告）日：2018-02-07

  Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

  本文提供了通过向有需要的个体施用治疗有效量的尖端钠依赖性胆汁酸转运体抑制剂（ASBTI）或其药学上可接受的盐，治疗或改善高胆汁血症或胆汁淤积性肝病的方法。还提供了治疗或改善肝病、降低血清胆汁酸或肝胆汁酸水平、治疗或改善瘙痒症、降低肝酶或降低胆红素的方法，包括向有需要的个体施用治疗有效量的ASBTI或其药学上可接受的盐。
• LIVER X RECEPTOR (LXR) MODULATORS
  申请人：Ellora Therapeutics, Inc.

  公开号：EP3626712A2

  公开（公告）日：2020-03-25

  Described herein are liver X receptor (LXR) modulators and methods of utilizing LXR modulators in the treatment of LXR-associated diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.

  本文描述了肝 X 受体（LXR）调节剂和利用 LXR 调节剂治疗 LXR 相关疾病、失调或病症的方法。本文还描述了含有此类化合物的药物组合物。
• RAD51 inhibitors and uses thereof
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US10421753B2

  公开（公告）日：2019-09-24

  The present invention includes novel RAD51 inhibitors. The compounds of the invention may be useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

  本发明包括新型 RAD51 抑制剂。本发明的化合物可用于预防或治疗有需要的受试者的癌症。本发明还包括通过向有需要的受试者施用治疗有效量的本发明化合物来预防或治疗癌症的方法。